The prognostic value of IPI in patients with primary breast lymphoma, a multicenter retrospective study

The prognostic value of IPI in patients with primary breast lymphoma, a multicenter retrospective study

Abstract Background Due to the rarity of PBL and the lack of large-scale studies, the prognostic value of IPI in PBL was controversial. Especially in the rituximab era, the ability of IPI to stratify prognosis in patients receiving immunochemotherapy was severely reduced. Then revised IPI (R-IPI) an...

Full description

Bibliographic Details
Main Authors: Kexin Feng, Shuangtao Zhao, Qingyao Shang, Guangdong Qiao, Jiaxiang Liu, Chenxuan Yang, Ya Wei, Yalun Li, Fei Ren, Lixue Xuan, Xiang Wang, Xin Wang
Format: Article
Language:English
Published: BMC 2022-11-01
Series:Cancer Cell International
Subjects:
Primary breast lymphoma (PBL)
IPI
R-IPI
NCCN-IPI
Rituximab
Breast cancer
Online Access:https://doi.org/10.1186/s12935-022-02772-y

Internet

https://doi.org/10.1186/s12935-022-02772-y

Similar Items